Research programme: multi-compound drug discovery - Nastech/Novo Nordisk
Latest Information Update: 03 Apr 2008
At a glance
- Originator Nastech Pharmaceutical Company; Novo Nordisk
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 15 Mar 2006 Preclinical trials in Undefined in USA (Intranasal)